Freeline to Present Data at the 2021 Virtual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) and the 17th Annual WORLDSymposium 2021

Published 26 Jan 2021

Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases, today announced that it will present two e-posters at the 2021 Virtual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) taking place 3-5 February 2021.

In addition, the Company will present data on its gene therapy programmes for Gaucher and Fabry Disease, in one oral platform presentation and three e-posters at the 17TH Annual WORLDSymposiumTM taking place 8-12 February 2021.

 

EAHAD Presentation Details

Title: Follow-up on a Novel Adeno Associated Virus (AAV) Gene Therapy (FLT180a) Achieving Normal FIX Activity Levels in Severe Hemophilia B (HB) Patients (B-AMAZE Study)
Presenter: Pratima Chowdary, Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free Hospital, University College London
Presentation #: ABS-114
Date and Time: Tuesday, 2 February 2021, 6:00 CET

Title: Insight into the Persistent Clinical Burden Underlying Problem Joints, Pain, and Bleeding in Adults from Across Europe with Haemophilia A and B: The CHESS II Study
Presenter: Sharmila Kar, Head of Real-World Evidence, Freeline
Presentation #: ABS-134
Date: Tuesday, 2 February 2021, 6:00 CET

The e-poster presentations will be available from Tuesday, 2 February 2021, as recordings on the events section of the Freeline website.

WORLDSymposiumTM Presentation Details

Platform presentation:

Title: FLT201: An AAV-Mediated Gene Therapy for Type 1 Gaucher Disease Designed to Target Difficult to Reach Tissues
Author: Romuald Corbau, Chief Scientific Officer, Freeline
Date and Time: Thursday, 11 February 2021, 11:36am EST

Poster presentations:

Title: FLT201: An AAV-Mediated Gene Therapy for Type 1 Gaucher Disease Designed to Target Difficult to Reach Tissues
Author: Romuald Corbau, Chief Scientific Officer, Freeline
Presentation #: 44
Date: Thursday, 11 February 2021

Title: Generation of β-Glucocerebrosidase Variants with Increased Half-Life in Human Plasma for Liver Directed AAV Gene Therapy Aimed at the Treatment of Type 1 Gaucher Disease
Author: Fabrizio Comper, Scientific Director, Freeline
Presentation #: 41
Date: Thursday, 11 February 2021

Title: Development of a GLA nAb Assay with a Fully-Human, Neutralizing IgG4 Positive Control to Characterize Antibody Response in Fabry Disease Patients
Author: Sujata Ravi, Scientist, Freeline
Presentation #: 211
Date: Thursday, 11 February 2021

The poster presentations will be available on the events section of the Freeline website from 2:30 pm EST on Monday, 8 February 2021. A recording of the platform presentation with a live Q&A will be available after the presentation concludes on Thursday, 11 February 2021, also on the events section of the Freeline website.